FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2553449120> ?p ?o ?g. }

• W2553449120 abstract "Abstract Abstract 4336 Background: Recent reports have suggested that aside from the tyrosine kinase inhibitory effect, dasatinib also promotes a clonal expansion of cytotoxic T-cells in patients with Philadelphia-chromosome positive (Ph+) leukemias. We sought to determine whether there is an absolute lymphocytosis in patients with Ph+ Acute Lymphocytic Leukemia (ALL) treated at our institution on 3 consecutive protocols. Method: We collected data on 122 patients with Ph+ ALL treated with 3 different regimens (hyperCVAD, hyperCVAD + imatinib, and hyperCVAD + dasatinib) from 1994 to 2010, who achieved a complete hematological response (CHR). We examined potential differences between the absolute numbers lymphocytes in peripheral blood (PB) and percentage lymphocytes in bone marrow (BM) at 3 stages: pretreatment, at CHR, and 3–6 months after CHR. Result: Thirty four (28%) patients received hyperCVAD, 43 (35%) hyperCVAD + imatinib, and 45 (37%) hyperCVAD + dasatinib. Twenty five (74%) of patients treated with hyperCVAD, 14 (33%) of patients treated with hyperCVAD + imatinib, and 5 (11%) of patients treated with hyperCVAD + dasatinib have relapsed on these sequential studies. The median PB absolute lymphocyte count for the 3 groups are as follow: Pretreatment: hyperCVAD: 3570.5/uL, hyperCVAD + imatinib: 2262/uL, hyperCVAD + dasatinib: 2376/uL (p = 0.1); at CR: hyperCVAD: 291.5/uL, hyperCVAD + imatinib: 168/uL, hyperCVAD + dasatinib: 239/uL (p = 0.3); 3 to 6 months after CR: hyperCVAD: 485/uL, hyperCVAD + imatinib: 450/uL, hyperCVAD + dasatinib: 632.5/uL (p = 0.26). The median BM lymphocyte percentages are as follow: Pretreatment: hyperCVAD: 3%, hyperCVAD + imatinib: 6%, hyperCVAD + dasatinib: 5% (p = 0.5). CHR: hyperCVAD: 6%, hyperCVAD + imatinib: 4%, hyperCVAD + dasatinib: 4% (p = 0.4). Three to 6 months after CHR: hyperCVAD: 5%, hyperCVAD + imatinib: 3%, hyperCVAD + dasatinib: 7% (p = 0.005). We then divided all patients by their 3 to 6 month BM lymphocyte percentages to 3 groups (< 3%, 3–6%, >6%). There was no difference in remission-free survival for these 3 groups (p=0.76)(Figure 1) Conclusion: Patients who received hyperCVAD + dasatinib had a statistically significant higher BM lymphocyte percentages, 3 to 6 month after achieving CHR than patients treated with the imatinib-containing regimen or chemotherapy alone. Whether this is a clonal population of effector T-cells and whether it plays an important role on the activity of dasatinib compared to imatinib or chemotherapy alone will need to be further investigated. Disclosures: Ravandi: Novartis: Honoraria, Speakers Bureau; Bristol- Myere- Squibb: Honoraria, Research Funding. Kantarjian:BMS, Pfizer and Novartis: Research Funding; Novartis: Consultancy. Cortes:Bristol Myers Squibb: Research Funding; Novartis: Research Funding; Pfizer: Consultancy, Research Funding. O'Brien:Novartis: Research Funding; BMS: Research Funding. Thomas:Novartis: Honoraria; Bristol-Meyer-Squibb: Honoraria; Amgen: Research Funding." @default.
• W2553449120 created "2016-11-30" @default.
• W2553449120 creator A5000750846 @default.
• W2553449120 creator A5006104041 @default.
• W2553449120 creator A5015101485 @default.
• W2553449120 creator A5016370927 @default.
• W2553449120 creator A5038307470 @default.
• W2553449120 creator A5046097970 @default.
• W2553449120 creator A5090435894 @default.
• W2553449120 date "2010-11-19" @default.
• W2553449120 modified "2023-10-15" @default.
• W2553449120 title "Higher Bone Marrow Lymphocyte Percentage 3 to 6 Month After Therapy with Hypercvad + Dasatinib Than That with Hypercvad + Imatinib or Hypercvad Alone In Patients with Philadelphia Chromosome Positive Acute Lymphoblastic Leukemia" @default.
• W2553449120 doi "https://doi.org/10.1182/blood.v116.21.4336.4336" @default.
• W2553449120 hasPublicationYear "2010" @default.
• W2553449120 type Work @default.
• W2553449120 sameAs 2553449120 @default.
• W2553449120 citedByCount "0" @default.
• W2553449120 crossrefType "journal-article" @default.
• W2553449120 hasAuthorship W2553449120A5000750846 @default.
• W2553449120 hasAuthorship W2553449120A5006104041 @default.
• W2553449120 hasAuthorship W2553449120A5015101485 @default.
• W2553449120 hasAuthorship W2553449120A5016370927 @default.
• W2553449120 hasAuthorship W2553449120A5038307470 @default.
• W2553449120 hasAuthorship W2553449120A5046097970 @default.
• W2553449120 hasAuthorship W2553449120A5090435894 @default.
• W2553449120 hasConcept C126322002 @default.
• W2553449120 hasConcept C141071460 @default.
• W2553449120 hasConcept C2777583451 @default.
• W2553449120 hasConcept C2778729363 @default.
• W2553449120 hasConcept C2779536868 @default.
• W2553449120 hasConcept C71924100 @default.
• W2553449120 hasConceptScore W2553449120C126322002 @default.
• W2553449120 hasConceptScore W2553449120C141071460 @default.
• W2553449120 hasConceptScore W2553449120C2777583451 @default.
• W2553449120 hasConceptScore W2553449120C2778729363 @default.
• W2553449120 hasConceptScore W2553449120C2779536868 @default.
• W2553449120 hasConceptScore W2553449120C71924100 @default.
• W2553449120 hasLocation W25534491201 @default.
• W2553449120 hasOpenAccess W2553449120 @default.
• W2553449120 hasPrimaryLocation W25534491201 @default.
• W2553449120 hasRelatedWork W202774629 @default.
• W2553449120 hasRelatedWork W2080060037 @default.
• W2553449120 hasRelatedWork W2288468725 @default.
• W2553449120 hasRelatedWork W2344488712 @default.
• W2553449120 hasRelatedWork W2531137772 @default.
• W2553449120 hasRelatedWork W2550429646 @default.
• W2553449120 hasRelatedWork W2560941332 @default.
• W2553449120 hasRelatedWork W2562703706 @default.
• W2553449120 hasRelatedWork W2565556836 @default.
• W2553449120 hasRelatedWork W2583320244 @default.
• W2553449120 hasRelatedWork W2589984089 @default.
• W2553449120 hasRelatedWork W2591848289 @default.
• W2553449120 hasRelatedWork W2592213658 @default.
• W2553449120 hasRelatedWork W2593545838 @default.
• W2553449120 hasRelatedWork W2594190718 @default.
• W2553449120 hasRelatedWork W2616269701 @default.
• W2553449120 hasRelatedWork W2904392588 @default.
• W2553449120 hasRelatedWork W2937713132 @default.
• W2553449120 hasRelatedWork W2979790281 @default.
• W2553449120 hasRelatedWork W2989462705 @default.
• W2553449120 isParatext "false" @default.
• W2553449120 isRetracted "false" @default.
• W2553449120 magId "2553449120" @default.
• W2553449120 workType "article" @default.